ICGEB’s training programmes represent an exciting opportunity to interact with people all over the world in state-of-the-art scientific environments and in all the top scientific institutes. Youth, essential to nurturing a brighter and more equitable future, constitutes the backbone of the ICGEB’s training programmes that have been operating for over three decades across the world.
ICGEB has an alumni network of over 3000 individuals from more than 60 countries around the globe, with 700 PhD awardees among them.
On the occasion of the UN International Day of Women and Girls in Science 2021, we are delighted to announce the launch of the ICGEB Alumni for Girls in STEM campaign.
We strive to strengthen this networking community, to develop training, cultural initiatives, and expertise involving ICGEB graduates. Through the support and ideas of its members and the proactive collaboration of the ICGEB, the Alumni will thrive and continue to advance biotechnology activities in academic institutes, companies, and industries where it is most needed.
“ICGEB had an enormous impact on my career. It provided anZulma Suares, Director, R&D, VECOL S.A., Bogota, Colombia
an international environment rich in experimental skills and ideas, leadership training and science diplomacy. Today I have a network of collaborations that have been developed through the ICGEB, following the rules of respect and excellence learned in Trieste.”
The ICGEB Alumni Map is a visualization of the Alumni network which showcases where our Alumni currently work. Browse the map to find where our alumni are today.The map indicates institutes/universities/companies in 53 countries across the world and is updated regularly.
More information on the Alumni, including contact details, are available in the ICGEB Alumni Network Registry, in the reserved area below. This Registry is made available exclusively to the Members of the ICGEB Alumni network who have shared their contact details for the purpose of strengthening cooperation amongst the ICGEB Alumni.
Where are our ICGEB Alumni today?
Camila Canaán-Haden Ayala, CIGB Cuba, was a recipient of a Short-term Postdoctoral Fellowship at the Cardiovascular Biology laboratory, generously funded by IILA.
Mobility: Immunotherapy of Cancer laboratory of Cuban CIG
Host Institute: Cardiovascular Biology Laboratory, ICGEB, Trieste, Italy.
Under the supervision of Serena Zacchigna, during a 3-month period from August to November 2019, the visiting junior scientist learned and practiced advanced techniques used in the host lab for her research projects on angiogenesis and cancer.
“As part of my technical training, as a visiting scientist I was able to develop immunofluorescence studies, Western Blotting, molecular characterization by PCR, flow cytometry, DNA and RNA extraction, and the culture of primary endothelial and fibroblastic cells from tissues and tumors. Handling of confocal and fluorescence microscopes was also part of the training. I acquired skills in the management of different advanced equipment, including a ChemiDoc Touch Imaging System, a Nano Photometer, Nano Drop, and the use of programmes to manage the equipment and their results (Image J, V4.4 and Nis-Elements AR).”
The acquired abilities will be useful in the characterisation of the leukocytes infiltrates induced by the VEGF-based immunotherapy procedure, and by other immunotherapy candidates now under development in Ms. Canaan-Haden’s laboratory in Cuba. “Another important component of the stay was the opportunity to participate in laboratory meetings and in seminars presented at ICGEB by leading scientists.”
In the lab of the visiting junior scientist, at the CIGB of Havana, one of the ongoing projects relates to the development of a specific active anti-tumor immunotherapy procedure that uses a mutated variant of human VEGF as antigen. Immunization with this molecule, in the presence of powerful adjuvants, induces the production of antibodies that block the pro-angiogenic activity of VEGF, and affect tumor growth and metastases in experimental animal models. This novel anti-tumor immunotherapy procedure (coded HeberSaVax or CIGB-247) is in Phase II clinical trials.
For more information:
Office of the Director-General
Email: [email protected]